Sanders Capital LLC Has $726.81 Million Stake in Johnson & Johnson (JNJ)

Share on StockTwits

Sanders Capital LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,397,505 shares of the company’s stock after acquiring an additional 100,000 shares during the quarter. Johnson & Johnson makes up 3.6% of Sanders Capital LLC’s portfolio, making the stock its 11th largest holding. Sanders Capital LLC’s holdings in Johnson & Johnson were worth $726,812,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of JNJ. BlackRock Inc. lifted its stake in shares of Johnson & Johnson by 4.7% during the 1st quarter. BlackRock Inc. now owns 175,389,024 shares of the company’s stock valued at $22,476,102,000 after buying an additional 7,853,141 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its stake in shares of Johnson & Johnson by 2.0% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 29,761,934 shares of the company’s stock valued at $3,813,993,000 after buying an additional 590,069 shares in the last quarter. Fisher Asset Management LLC lifted its stake in shares of Johnson & Johnson by 3.8% during the 2nd quarter. Fisher Asset Management LLC now owns 13,118,604 shares of the company’s stock valued at $1,591,811,000 after buying an additional 478,982 shares in the last quarter. Boston Partners lifted its stake in shares of Johnson & Johnson by 68.7% during the 1st quarter. Boston Partners now owns 12,783,909 shares of the company’s stock valued at $1,638,258,000 after buying an additional 5,207,124 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its stake in shares of Johnson & Johnson by 4.7% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 8,590,694 shares of the company’s stock valued at $1,100,897,000 after buying an additional 383,040 shares in the last quarter. Institutional investors and hedge funds own 66.67% of the company’s stock.

In other news, CAO Ronald A. Kapusta sold 7,899 shares of the business’s stock in a transaction dated Friday, September 7th. The shares were sold at an average price of $137.18, for a total value of $1,083,584.82. Following the sale, the chief accounting officer now directly owns 25,725 shares in the company, valued at approximately $3,528,955.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Michael E. Sneed sold 29,000 shares of the business’s stock in a transaction dated Monday, August 27th. The stock was sold at an average price of $134.80, for a total transaction of $3,909,200.00. Following the completion of the sale, the chief operating officer now owns 59,124 shares in the company, valued at $7,969,915.20. The disclosure for this sale can be found here. 0.22% of the stock is owned by insiders.

Shares of JNJ stock opened at $139.05 on Friday. The firm has a market capitalization of $374.16 billion, a price-to-earnings ratio of 19.05, a P/E/G ratio of 2.21 and a beta of 0.70. Johnson & Johnson has a 52 week low of $118.62 and a 52 week high of $148.32. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.33 and a current ratio of 1.65.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 16th. The company reported $2.05 EPS for the quarter, topping the consensus estimate of $2.03 by $0.02. The business had revenue of $20.35 billion for the quarter, compared to analysts’ expectations of $20.05 billion. Johnson & Johnson had a net margin of 1.89% and a return on equity of 34.97%. The business’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.90 EPS. As a group, equities analysts expect that Johnson & Johnson will post 8.16 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 11th. Shareholders of record on Tuesday, November 27th will be paid a $0.90 dividend. This represents a $3.60 annualized dividend and a yield of 2.59%. The ex-dividend date is Monday, November 26th. Johnson & Johnson’s payout ratio is currently 49.32%.

JNJ has been the topic of a number of analyst reports. Raymond James lifted their target price on shares of Johnson & Johnson from $144.00 to $149.00 and gave the company an “outperform” rating in a research note on Wednesday. Credit Suisse Group lifted their target price on shares of Johnson & Johnson from $149.00 to $152.00 and gave the company an “outperform” rating in a research note on Wednesday. Goldman Sachs Group upgraded shares of Johnson & Johnson from a “sell” rating to a “neutral” rating in a research note on Thursday, July 12th. Sanford C. Bernstein initiated coverage on shares of Johnson & Johnson in a research note on Wednesday, June 27th. They set a “market perform” rating and a $129.00 target price on the stock. Finally, ValuEngine upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Saturday, July 28th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $141.54.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Story: Treasury Bonds

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Dimensional Fund Advisors LP Acquires 7,024 Shares of Total System Services, Inc.
Dimensional Fund Advisors LP Acquires 7,024 Shares of Total System Services, Inc.
F.N.B. Corp  Shares Bought by Dimensional Fund Advisors LP
F.N.B. Corp Shares Bought by Dimensional Fund Advisors LP
OneMain Holdings Inc  Shares Bought by Dimensional Fund Advisors LP
OneMain Holdings Inc Shares Bought by Dimensional Fund Advisors LP
GAM Holding AG Buys 342 Shares of IDEXX Laboratories, Inc.
GAM Holding AG Buys 342 Shares of IDEXX Laboratories, Inc.
Tapestry Inc  Shares Bought by Mirae Asset Global Investments Co. Ltd.
Tapestry Inc Shares Bought by Mirae Asset Global Investments Co. Ltd.
Brian James Harris Acquires 2,000 Shares of Summit Materials Inc  Stock
Brian James Harris Acquires 2,000 Shares of Summit Materials Inc Stock


© 2006-2018 Ticker Report